{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=urate+oxidase&page=2",
    "query": {
      "intervention": "urate oxidase",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=urate+oxidase&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=urate+oxidase&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T03:40:43.079Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01097369",
      "title": "Elitek (Rasburicase) Immuno-Monitoring Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tumor Lysis Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2010-02",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 4,
      "location_summary": "Valhalla, New York • Oklahoma City, Oklahoma • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097369"
    },
    {
      "nct_id": "NCT01830725",
      "title": "Purine Metabolism Enzyme SNP to Uric Acid Production",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gout",
        "Hyperuricemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Keesler Air Force Base Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-12",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 1,
      "location_summary": "Keesler Air Force Base, Mississippi",
      "locations": [
        {
          "city": "Keesler Air Force Base",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830725"
    },
    {
      "nct_id": "NCT04987294",
      "title": "Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "ALLN-346",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 19,
      "start_date": "2022-09-02",
      "completion_date": "2022-09-02",
      "has_results": false,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987294"
    },
    {
      "nct_id": "NCT04513366",
      "title": "A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Gout"
      ],
      "interventions": [
        {
          "name": "SEL-212 low-dose",
          "type": "DRUG"
        },
        {
          "name": "SEL-212 high-dose",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 112,
      "start_date": "2020-08-18",
      "completion_date": "2022-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 40,
      "location_summary": "Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04513366"
    },
    {
      "nct_id": "NCT00325195",
      "title": "Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "pegloticase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Savient Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2006-05",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2011-02-28",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325195"
    },
    {
      "nct_id": "NCT04829435",
      "title": "Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout"
      ],
      "interventions": [
        {
          "name": "ALLN-346",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-04-21",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04829435"
    },
    {
      "nct_id": "NCT04236219",
      "title": "ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "ALLN-346",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allena Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-09-02",
      "completion_date": "2020-11-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04236219"
    },
    {
      "nct_id": "NCT01021241",
      "title": "Safety and Efficacy Study of Intravenous Uricase-PEG 20",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gout",
        "Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Uricase-PEG 20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "EnzymeRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-10",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2010-02-23",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Duncansville, Pennsylvania",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021241"
    },
    {
      "nct_id": "NCT07535034",
      "title": "A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Dotinurad",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Crystalys Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-05-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07535034"
    },
    {
      "nct_id": "NCT03316131",
      "title": "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asymptomatic Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Verinurad",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matched placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-10-25",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-02T03:40:43.079Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316131"
    }
  ]
}